See the latest vacancies and find out about working for MSF UKJobs in the UK
TB PRACTECAL | A cutting-edge clinical trial
TB PRACTECAL is an MSF-sponsored clinical trial that's evaluating new approaches to combat drug-resistant tuberculosis (TB).
Know as DR-TB, this strain of the disease does not respond to first-line antibiotics and can require an arduous treatment.
"The side effects of the medicines people currently take are often described as worse than the disease itself: nausea, headaches, deafness, psychosis," says Bern-Thomas Nyang'wa, who leads the study.
"Patients have to take up to 20 pills a day, alongside painful injections, and treatment can last more than two years."
An estimated 600,000 people worldwide are living with multidrug-resistant or extremely drug-resistant TB.
The TB PRACTECAL trial has sites around the world, currently monitoring over 100 patients in the search to find a less toxic treatment for those affected by the disease.